CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
OPERATING ACTIVITIES:
Net income	$ 35,068	$ 45,394	$ (369)	$ 9,180	$ 80,462	$ 8,811
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					58,968	58,826
Non-cash impairment charges					2,754	0
Deferred income tax (benefit) provision					(4,907)	(401)
Share-based compensation					22,033	8,922
Amortization of debt issuance costs and expenses associated with debt refinancing					3,569	5,551
Non-cash lease expense					2,528	1,760
Accretion of bond issuance discount					0	6,780
Loss on disposal of property and equipment					86	517
Gain from the sale of business	679		0		(42,197)	0
Change in fair value of contingent consideration and others					(385)	(708)
Changes in assets and liabilities:
Accounts receivable					10,802	95,293
Inventories					2,893	(47,041)
Prepaid expenses and other current assets					(8,061)	2,191
Other non-current assets					4,067	6,149
Accounts payable, accrued expenses and other current liabilities					27,277	(88,671)
Other non-current liabilities					482	(4,048)
Net cash provided by operating activities					160,371	53,931
INVESTING ACTIVITIES:
Purchases of property and equipment					(13,309)	(23,736)
Proceeds from sale of Extremity Orthopedics business					191,736	0
Proceeds from sale of property and equipment					0	3,302
Cash (paid) provided for business acquisitions, net of cash acquired					(303,910)	0
Acquired in-process research and development					0	(5,000)
Net cash used in investing activities					(125,483)	(25,434)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness					2,200	127,700
Payments on debt					(102,200)	(388,500)
Purchase of option hedge on convertible notes					0	(104,248)
Proceeds from convertible notes issuance					0	575,000
Proceeds from sale of stock purchase warrants					0	44,563
Payment of debt issuance costs					(249)	(20,264)
Purchases of treasury stock					0	(100,000)
Proceeds from exercised stock options					3,603	3,598
Cash taxes paid in net equity settlement					(3,844)	(4,397)
Net cash (used) provided by financing activities					(100,490)	133,452
Effect of exchange rate changes on cash and cash equivalents					(7,150)	121
Net increase in cash and cash equivalents					(72,752)	162,070
Cash and cash equivalents at beginning of period		$ 470,166		$ 198,911	470,166	198,911	$ 198,911
Cash and cash equivalents at end of period	$ 397,414		$ 360,981		$ 397,414	$ 360,981	$ 470,166